Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Skin sensitisation

Currently viewing:

Administrative data

Endpoint:
skin sensitisation: in vitro
Type of information:
experimental study
Adequacy of study:
key study
Study period:
2017
Reliability:
1 (reliable without restriction)

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2017
Report date:
2017

Materials and methods

Test guideline
Qualifier:
according to guideline
Guideline:
OECD Guideline 442D (In Vitro Skin Sensitisation: ARE-Nrf2 Luciferase Test Method)
GLP compliance:
yes
Type of study:
other: The LuSens test
Justification for non-LLNA method:
The LuSens test is an ARE Reporter Gene Assay that was developed by the BASF SE (Ludwigshafen, Germany) and is based on the OECD 442D Guideline (KeratinoSens As-say). The assay differs in some points from the OECD guideline.

Test material

Constituent 1
Chemical structure
Reference substance name:
3-acetylthiazolidine-4-carboxylic acid
EC Number:
225-713-6
EC Name:
3-acetylthiazolidine-4-carboxylic acid
Cas Number:
5025-82-1
Molecular formula:
C6H9NO3S
IUPAC Name:
3-acetylthiazolidine-4-carboxylic acid

Results and discussion

In vitro / in chemico

Results
Key result
Run / experiment:
other:
Parameter:
other: Luciferase induction
Value:
0
Vehicle controls validity:
valid
Negative controls validity:
valid
Positive controls validity:
valid

Applicant's summary and conclusion

Conclusions:
Under the experimental conditions of this study, the test item, 3-acetylthiazolidine-4-carboxylic acid, was negative in the LuSens assay and is therefore considered not having the potential to activate the Nrf2 transcription factor.